Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) said on Thursday that it has launched its butalbital acetaminophen and caffeine (BAC) capsule in 50mg/300mg/40mg in the United States for the treatment of tension headache (migraine).
It comes after the company received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application for BAC.
US sales of BAC capsule 50mg/300mg/40mg were approximately USD40m for the 12 months ending 31 March 2020, according to IQVIA.
Mayne Pharma markets more than 60 generic and specialty branded pharmaceuticals in the US.
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval